Monograph Details
|
|
Ob/Gyn
> Infertility
|
|
MENOPUR |
| Manufacturer |
|
Ferring Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Generic Name |
|
Menotropins (follicle-stimulating hormone 75 IU + luteinizing hormone 75 IU); per vial; pwd for SC inj after reconstitution. |
| Indications |
|
Stimulation of multiple follicles in ovulatory patients undergoing Assisted Reproductive Technologies (ART) who have previously received pituitary suppression. |
| Children |
Not applicable.
|
| Adults |
|
Individualize. Initially 225 IU SC inj daily; adjust based on response in increments of up to 150 IU at intervals of at least 2 days; max 450 IU daily; usual max 20 days. Induce final maturation of follicles with hCG (see Precautions). See literature. |
| Contraindications |
|
Primary ovarian failure. Uncontrolled thyroid or adrenal disease. Intracranial lesions. Undiagnosed abnormal vaginal bleeding. Ovarian cysts or enlargement. Tumor of pituitary, breast, ovary, or uterus. Pregnancy (Cat.X). |
| Precautions |
|
Do complete gynecological and endocrinological exam first. Thromboembolic disorders. Do not give hCG if high estrogen levels or excessive numbers of ovarian follicles by ultrasound indicate a high risk of ovarian hyperstimulation syndrome (OHSS). Nursing mothers. |
| Adverse Reactions |
|
OHSS with pulmonary and vascular complications, ovarian enlargement, headache, abdominal pain, GI upset, inj site reactions, risk of high order multiple births. |
| How Supplied |
|
Vials (w. diluent)—5 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
